Teva To Enter US Advair Generic Approval Fray Next Year
This article was originally published in Scrip
Executive Summary
Teva plans to file for US approval next year of its multidose dry powder inhaler (mDPI) products containing fluticasone propionate/salmeterol, a generic of GlaxoSmithKline's blockbusting Advair, plus fluticasone propionate alone, it said after reporting positive top-line Phase III data for them both.